Abstract
Advanced gastrointestinal (GI) malignancies are varied in presentation, prognosis, and treatment options. With the exception of resectable recurrent colorectal cancer, metastatic GI malignancies are incurable. Cytotoxic chemotherapies have been the mainstay of therapy for decades but limited extension of survival or clinical benefit has been achieved in non-colorectal GI cancers. There has been great interest in the incorporation of antiangiogenic strategies to improve outcomes for these patients. Clear benefits have been identified with bevacizumab and sorafenib in colorectal cancer and hepatocellular cancer, respectively; other GI tumor sites have lacked impressive results with antiangiogenic agents. In this review, we will present the benefits, or lack thereof, of clinically tested antiangiogenic compounds in GI malignancies and explore some potential new therapeutic anti-angiogenesis options for these diseases.
Highlights
Up-regulation of angiogenesis is required for development of malignancy, tumor growth and progression [1,2]
Antiangiogenic agents have clearly advanced the treatment of GI malignancies, most notably colorectal cancer (CRC) and Hepatocellular Carcinoma (HCC)
There have been no advances in the treatment of incurable ESOPHAGOGASTRIC CANCERS (EGC) and pancreas cancer using antiangiogenic agents and prognosis remains poor
Summary
Up-regulation of angiogenesis is required for development of malignancy, tumor growth and progression [1,2]. The Asia-Pacific trial enrolled patients from China, South Korea and Taiwan and had hepatitis B as the predominant HCC risk factor Both studies demonstrated a significant OS improvement (SHARP: 10.7 vs 7.9 months, HR 0.69, p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
